Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Brett Nelson who wrote (101)	1/24/1998 5:18:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 668

I've heard a royalty figure for OP-1 from Stryker upon approval of roughly $80MM per year. That number could be totally bogus, but if true it would support a much higher stock price. If OP-1 proceeds on other indications like renal failure, then milestone payments and royalties from Biogen would pile up as well. So, I think a significantly higher price would be appropriate if these scenarios play out.

To: Brett Nelson who wrote (101)	1/30/1998 6:57:00 PM
From: Boyce Burge	Read Replies (1) \| Respond to of 668

I understand the results of the bone knitting clin trial of OP-1 will be announced in New Orleans on 20 March. Based on that date and a probable favorable report, I think we will see a gradual rise to about $10/sh up to the 20th, and then maybe a pop to 12 on the good news, if it is good news. since fda approval will still be a ways off, I would guess it would subside to 10-11 within a few days or weeks after that. Bad news, and we will see it at 6....